Jamna Auto has long been sold as a predictable proxy to the commercial-vehicle (CV) cycle: a market leader in leaf springs, expanding into value-added lift axles and air suspensions. But when we stitch together the Q1 and Q2 FY26 numbers, the board disclosures, and the cash-flow statements, a very different picture emerges one where **execution momentum has slowed**, **working capital has exploded**, and the company appears to be entering a **capital-cycle downshift**, not an upcycle.



# Execution Pace & Credibility Override

**The entire thesis starts breaking here.**

Execution slowdown is not visible in one quarter — it appears clearly when we align **Q1 + Q2 FY26**.

# A. Revenue contraction in Q2 is not seasonal

Q1 FY26 revenue: **₹573cr**  
Q2 FY26 revenue: **₹531cr** 

In a normal CV cycle, Q2 improves over Q1. It didn’t.  
This is the first sign of **demand not translating into orders**.

# B. Profitability falls quarter-on-quarter

* Q1 PBT: **₹64.49cr** 
* Q2 PBT: **₹56cr** (Consolidated P&L) 

Margins not just stagnated  they **compressed**, despite commissioning of the new plant.

# C. Zero progress on product-mix transformation

Share of new products: **24%** (same as last year).

Years of narrative about lifting margins through premium suspension systems shows **no execution on ground**.

# D. Disclosure weakness

The company does not provide utilisation or revenue visibility for the newly commissioned Adityapur plant   
This lack of clarity during a capex cycle is a **credibility warning**.

**Verdict:**  
Before looking at valuation or growth fantasies, execution is **slowing**, credibility on margin recovery is **weak**, and strategy claims are not showing up in the numbers.



BUSINESS MODEL DIAGNOSIS — A Moat That Isn’t Widening

Jamna’s model depends on three pillars:

1. OEM CV demand
2. Aftermarket scale
3. New products (lift axle, air suspension)

Across all three, FY26 shows **no structural strengthening**.

# OEM Dependency

OEMs stretch payment terms aggressively.  
This shows up sharply in Q2 receivables.

# Aftermarket

No meaningful delta disclosed this year. Volumes not scaling fast enough to offset OEM cyclicality.

# New Products

Still **24%** of revenue  unchanged despite multi-year commentary.

This means Jamna remains a **commodity auto-component maker**, not a premiumisation story.



#  WORKING CAPITAL FORENSICS The Real Breaker of the Thesis

This is where the story flips.

# A. Receivables explode in Q2

Trade receivables:

* Mar 2025: **₹13,575 lakh**
* Sept 2025: **₹24,890 lakh** (+83%) 

Sales only grew \~3% YoY.  
Such a gap is impossible without:

* delayed payments from OEMs,
* or revenue pushed via extended credit,
* or deterioration in collection quality.

This is a **major red flag**.

# B. Inventory build begins in Q1

Q1 inventory change: **–₹1,836 lakh** (means inventory increased).  
Pg 4 Consolidated P&L.

Building inventory **before** a Q2 revenue drop is the worst possible alignment.

# C. Payables do not increase proportionally

Which means Jamna is funding WC from its own balance sheet — not OEMs, not suppliers.

# D. Cash collapse

Cash and cash equivalents fall from:

* **₹13,968 lakh → ₹5,847 lakh** (H1 FY26) Cash flow 

Combined CFO of Q1+Q2 is insufficient to cover WC + capex → **negative free cash flow**.

This is a smoking gun:  
The company is consuming cash faster than it can generate it.

**Manu Interpretation:**  
This is the classic pattern preceding a **capital-cycle downturn**:  
High capex → weak utilisation → working-capital blowout → ROCE compression.



#  ROCE TRAJECTORY  Inevitable Compression

ROCE falls when either:

* margins shrink,
* or working capital rises,
* or fixed assets expand without revenue scaling.

Jamna is hitting **all three simultaneously**.

# Evidence:

* Margins: Falling Q1→Q2.
* Receivables: +83%.
* Inventory: Rising.
* CWIP: Still high  capex not completed.
* Depreciation rising as new assets capitalise.

This guarantees **ROCE will fall materially in FY26**.

A falling ROCE in a low-moat business → **valuation derating**.

# CASH FLOW DIAGNOSIS  The Hard Truth

# Operating Cash Flow before WC:

Strong at ₹14,941 lakh (H1).  
But that’s where the good news ends.

# Working Capital absorption:

\~₹8,032 lakh (H1).

# Capex:

₹11,297 lakh in H1.

# Net cash outflow:

**–₹8,021 lakh** (H1).  


Jamna is burning cash **despite stable margins** — because operations are not translating into cash conversions.

This is the **definition of a weakening business cycle**.



# SHAREHOLDING & GOVERNANCE SIGNALS

# A. Promoter holding: 50%

Stable but unchanged.

# B. Low institutional ownership (7%)

Institutions avoid businesses with:

* weak moats,
* high OEM dependency,
* volatile cash cycles.

# C. Dividend payout despite cash stress

Interim dividend of ₹1 declared.  
Board Outcome Pg 1.

This is poor capital allocation inside a tightening liquidity environment.



# 7️⃣ WHAT’S THE REAL RISK?

Jamna is not dying.  
Jamna is not fraudulent.  
Jamna is not losing its OEM relationships.

The risk is simpler and more mechanical:

# It is turning into a low-growth, low-ROCE, cash-burning ancillary at exactly the point when the CV cycle is flattening.



#  6–12 MONTH OUTLOOK  Scenario Grid

# 🇮🇳 Base Case (65%) – Range-Bound to Negative

* Revenue: +2–5%
* Margins: flat to slightly lower
* Receivables remain high
* ROCE falls
* Cash generation weak **Stock trades sideways or corrects modestly.**

#  Downside Case (25%) – CV cycle softens

* OEMs reduce orders
* WC worsens
* Borrowings rise **Stock derates 20–30%.**

# Upside Case (10%) – Demand surprise + WC normalisation

* Receivables drop
* Plant utilisation improves
* Aftermarket accelerates **Stock re-rates 15–20%, but still capped by business model limits.**



#  FINAL VERDICT — WHAT THIS STORY REALLY MEANS

Jamna Auto is transitioning from a **growth + premiumisation narrative** to a **capital-cycle stress story**.

The signs are unambiguous:

* Execution is slowing.
* Product mix is stagnant.
* Working capital is exploding.
* Cash is collapsing.
* Capex is mistimed.
* ROCE will fall.

This combination does not support a long-term compounding case.

**Jamna today is a tactical trade, not a fundamental holding.**  
Investors should wait for:

1. Receivables to normalise sharply.
2. Clear utilisation and ROCE impact of the new plant.
3. Evidence that aftermarket and new products truly scale.

Until then, this remains a **CV-cycle-beta stock**, not a compounding machine.

Jamna Auto Looks Weaker Than It Seems The Numbers Tell a Different Story